Skip to content
OpenCapital
Get started

Oric Pharmaceuticals, Inc. ORIC Research and development expense

Research and development expense at other companies

Pfizer logo
PfizerPFE
——
Erasca, Inc. logo
Erasca, Inc.ERAS
——

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.4%
Enterprise value$923.07M+23.9%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0×0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s research and development expense?
Oric Pharmaceuticals, Inc. (ORIC) reported research and development expense of $31.44M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s research and development expense changed year-over-year?
Oric Pharmaceuticals, Inc.'s research and development expense increased by 27.6% year-over-year, from $24.64M to $31.44M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s research and development expense?
Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s research and development expense has grown at a 17.9% compound annual growth rate (CAGR), from $56.86M to $109.82M.